Methods of treating cancer with anti-PD-L1 antibodies

A PD-L1, HVR-L1 technology, applied in the field of cancer treatment with anti-PD-L1 antibodies, can solve problems such as enhancing CD8+ T cell-mediated tumor killing

Pending Publication Date: 2022-04-01
F HOFFMANN LA ROCHE & CO AG
View PDF141 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, inhibition of PD-L1 / PD-1 interaction may enhance CD8+ T cell-mediated tumor killing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating cancer with anti-PD-L1 antibodies
  • Methods of treating cancer with anti-PD-L1 antibodies
  • Methods of treating cancer with anti-PD-L1 antibodies

Examples

Experimental program
Comparison scheme
Effect test

example

[0366] The foregoing written description is considered sufficient to enable any person skilled in the art to practice the invention. The following examples are provided for illustrative purposes only and are not intended to limit the scope of the invention in any way. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and are within the scope of the appended claims.

[0367] overview

[0368]Immune checkpoint inhibition targeting programmed death-ligand 1 (PD-L1) or programmed death-1 (PD-1) has become an important approach for the treatment of various human cancers because PD-L1 is involved in tumor cells and tumor infiltration Expression on immune cells can suppress anticancer immune responses (Chen et al. (2013) Immunicty doi:10.1016 / j.immuni.2013.07.012). Atezolizumab is a humanized, engineered monoclonal immunoglobulin (Ig) G1 antibody that selecti...

example 1

[0383] Pharmacokinetic properties of atezolizumab monotherapy

[0384] In this example, the pharmacokinetic (PK) characteristics of atezolizumab were compared in eight atezolizumab studies conducted in the monotherapy setting (see Table 1). Key PK features such as C min 、C max and AUC were calculated based on clinical studies using a fixed 1200mg q3w dose and estimated for fixed 1680mg q4w and 840mg q2w doses. Important patient characteristics were also analyzed as potential covariates.

[0385] Atezolizumab PK was linear over the atezolizumab dose range of 1 to 20 mg / kg, including the fixed 1200 mg atezolizumab dose. Atezolizumab PK appeared to be comparable across studies, as similar cycle 1 C was observed at the same dose levels max and C min Shown (Table 2).

[0386] Table 2. Summary Statistics of Atezolizumab Serum PK Parameters in Cycle 1 of PCD4989g, JO28944, IMvigor210, IMvigor211, BIRCH, POPLAR, FIR, and OAK

[0387]

[0388]

[0389] method

[0390] s...

example 2

[0450] Exposure-response relationship of atezolizumab in urothelial carcinoma and non-small cell lung cancer

[0451] Exposure-response (ER) analyzes were performed to assess the possible relationship between clinical efficacy and atezolizumab exposure in separate (UC or NSCLC) and pooled (UC and NSCLC) patient populations for each indication.

[0452] method

[0453] Merged ER Analysis Overview

[0454] Objective response rate, overall survival and adverse events were assessed in comparison to pharmacokinetic (PK) measures, as described below.

[0455] Perform ER analysis to inform any relationship between PK measures and ORR, OS, grade 3 to 5 AEs, and AESI endpoints assessed in previous clinical studies based on cycle 1 data to minimize potential confounding from baseline prognostic factors Bias (Yang et al., (2013) J Clin Pharmacol doi:10.1177 / 0091270012445206; Wang et al., (2014) Clin Pharmacol Ther doi:10.1038 / clpt.2014.24) and observations for atezolizumab and other ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates to methods, uses, and kits related to the treatment of cancer by administering an anti-PD-L1 antibody (e.g., Atezumab) to a patient. In some embodiments, the anti-PD-L1 antibody is administered at 840 mg per 2 weeks or at 1680 mg per 4 weeks for two or more cycles.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 843,233, filed May 3, 2019, the contents of which are hereby incorporated by reference in their entirety. [0003] Submit a sequence listing as an ASCII text file [0004] The contents of the following submitted ASCII text file are hereby incorporated by reference in their entirety: Sequence Listing in Computer Readable Format (CRF) (file name: 146392045040SEQLIST.TXT, date of record: April 17, 2020, size: 24KB). technical field [0005] The present disclosure relates to methods, uses and kits related to the treatment of cancer by administering an anti-PD-L1 antibody (eg, atezolizumab). Background technique [0006] PD-L1 is overexpressed in many cancers and is often associated with poor prognosis (Okazaki T et al., Intern. Immun. 2007 19(7):813) (Thompson RH et al., Cancer Res 2006, 66(7):3381). Interestingly, in contrast to T lymphocytes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395C07K16/22C07K16/28A61K45/06A61P35/00A61K31/282A61K31/337A61K31/7048
CPCC07K16/2827A61K2039/545A61P35/00A61K39/395C07K16/22A61K2039/505A61K45/06A61K2300/00A61K31/282A61K31/337A61K31/7048A61K39/3955A61K2039/54C07K2317/56
Inventor D·S·Y·陈C·埃亨A·B·桑德勒
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap